What Cagrilintide is
Cagrilintide is a synthetic 37-residue peptide analogue of amylin, engineered with amino-acid substitutions and a fatty-acid side chain to give a substantially extended half-life relative to native amylin. It has been developed pharmaceutically as an investigational agent in metabolic research.
Molecular information
- Compound class: Long-acting amylin analogue
- Number of residues: 37 (plus a fatty-acid side chain)
- Approximate monoisotopic mass: ~3.7 kDa (varies with salt/counter-ion; consult the batch COA)
- Physical form: Typically supplied as a white lyophilised powder
Areas of published research
Preclinical and clinical research has investigated Cagrilintide in the context of amylin receptor signalling and metabolic outcomes. Its size and fatty-acid modification make high-resolution mass spectrometry the appropriate technique for identity confirmation; peak-area purity is assessed by reversed-phase HPLC with adequate gradient resolution to separate related-sequence impurities.
Analytical considerations
Standard research-peptide analytical checks apply: identity confirmation by mass spectrometry (see LC-MS peptide testing explained), purity assessment by reversed-phase HPLC at 214 nm (see what is HPLC peptide testing), and batch-specific documentation (see how to read a peptide COA). Refer to the Peptovia Research Certificate of Analysis page for live examples of the analytical format used for batches supplied.
Further reading
Peer-reviewed literature on Cagrilintide is accessible via PubMed and specialist journals. Readers are encouraged to evaluate primary sources directly rather than relying on secondary summaries.
Research Use Only. This profile is an educational overview of Cagrilintide as a research peptide. It does not describe or recommend human, veterinary or clinical use. Peptovia Research supplies Cagrilintide strictly for in-vitro laboratory research. No dosing, administration or therapeutic guidance is provided or implied.